微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 44.51% | 2.07% | 2.84% | 86/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 43.28% | -7.15% | 2.17% | 89/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 42.36% | -6.64% | -11.1% | 89/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 47.65% | -14.98% | 9.27% | 81/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 43.61% | -19.27% | -6.44% | 88/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 46.61% | -15.78% | 2.73% | 84/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 45.37% | -18.9% | -19.05% | 80/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 56.05% | -9.07% | 3.76% | 64/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 54.02% | -10.66% | -2.39% | 69/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 55.34% | -8.38% | -1.08% | 66/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 55.95% | -5.09% | -9.24% | 60/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 61.64% | -2.61% | 1.95% | 48/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 60.46% | -3.74% | 0.09% | 53/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 60.41% | -3.54% | 2.48% | 56/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 58.94% | -5.46% | -6.87% | 54/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 63.29% | 0.78% | 0.77% | 52/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 62.81% | 1.6% | 0.29% | 51/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 62.63% | 2.56% | 0.44% | 52/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 62.35% | 4.93% | -0.72% | 50/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 62.8% | -10.67% | 1.59% | 58/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 61.82% | -19.95% | 1.24% | 50/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 61.06% | -11.95% | 2.76% | 55/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 59.42% | -24.36% | -15.48% | 51/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 70.31% | 120.16% | -8.96% | 37/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 77.23% | 128.28% | 11.35% | 21/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 69.35% | 108.12% | -11.72% | 34/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 78.56% | 144.99% | 146.01% | 18/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 31.93% | -3.11% | -5.6% | 115/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 33.83% | 2.37% | 1.52% | 89/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 33.32% | 6.95% | 3.92% | 95/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 32.07% | 5.69% | -2.71% | 88/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 32.96% | 2.33% | -0.26% | 107/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 33.05% | -0.72% | 6.06% | 82/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 31.16% | -4.27% | 2.69% | 88/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 30.34% | -3.29% | -5.8% | 86/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 32.21% | 0.71% | -3.23% | 91/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 33.28% | 3.35% | 2.26% | 70/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 32.55% | 6.21% | 3.74% | 74/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 31.37% | 6.96% | -1.9% | 62/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 31.98% | 9.39% | -0.7% | 86/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 32.21% | 10.36% | 5.1% | 57/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 30.64% | 7.92% | 4.47% | 69/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 29.33% | 8.56% | 0.33% | 58/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |